ALARF Stock UPDATES Alaris Royalty (ALARF) 29.5728 08/22/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Alaris Royalty (ALARF) 29.5728 $ALARF

EnWave Appoints New Executive Chairman, Announces Change in Management, Private Placement with Director and Grants Stock Options
Marketwire - Mon Jun 23, 8:05AM CDT
EnWave Corporation (TSX VENTURE: ENW)(FRANKFURT: E4U) ("EnWave", or the "Company" is pleased to announce the appointment of Mr. John P.A. Budreski as a Director and Executive Chairman of the Board of EnWave.

March of Dimes Canada Retrofit Vehicle Initiative
Marketwire Canada - Fri Jan 17, 12:00PM CST
March of Dimes Canada, a charity that provides programs and services to children and adults with disabilities, will be donating up to $15,000 to help a family or individual living with disabilities in British Columbia retrofit a vehicle to become accessible.

TransCanada to Present at CIBC World Markets Whistler Institutional Investor Conference
Marketwire Canada - Fri Jan 17, 11:57AM CST
Russ Girling, president and chief executive officer for TransCanada Corporation (TSX:TRP) (NYSE:TRP) (TransCanada) will be presenting on January 23, 2014 at the CIBC World Markets - 2014 Whistler Institutional Investor Conference in Whistler, British Columbia.

Cooper Tire & RubberCorporate Event Announcement Notice
Wall Street Horizon - Thu Dec 19, 7:48PM CST
Trading resumes in:

Courier CorporationCorporate Event Announcement Notice
Wall Street Horizon - Thu Dec 19, 7:48PM CST
The following issues have been halted by IIROC:

IIROC Trade Resumption - Alaris Royalty Corp.
Newsfile Corp - Tue Jun 25, 11:29AM CDT
Trading resumes in:

IIROC Trade Halt - Alaris Royalty Corp.
Newsfile Corp - Tue Jun 25, 8:41AM CDT
The following issues have been halted by IIROC:

Alaris Declares Previously Announced Increased Monthly Dividend
Marketwire - Tue Jun 18, 7:31AM CDT
NOT FOR DISTRIBUTION IN THE UNITED STATES OR TO UNITED STATES NEWS AGENCIES

Alaris Royalty Corp Releases First Quarter Financial Results
Marketwire - Mon May 06, 7:02AM CDT
Alaris Royalty Corp. ("Alaris" or the "Corporation" (TSX: AD) today announced its results for the three months ended March 31, 2013.

Alaris Royalty Corp. Declares April Dividend
Marketwire - Thu Apr 18, 6:01AM CDT
Alaris Royalty Corp. ("Alaris" or the "Corporation" (TSX: AD) announces that the Board of Directors of the Corporation has declared a dividend of $0.105 per common share, representing $1.26 per share on an annualized basis. The dividend is payable on May 15, 2013 to holders of record on April 30, 2013. The ex-dividend date is April 26, 2013.

Alaris Royalty Corp. Announces Retirement of Clay Riddell as Director
Marketwire - Mon Mar 25, 4:07PM CDT
The Board of Directors (the "Board" of Alaris Royalty Corp. ("Alaris" or the "Corporation" (TSX: AD) wishes to announce that Mr. Clay Riddell will retire from the Board and will not be seeking re-election to the Board at the Corporations upcoming annual general and special meeting of its shareholders to be held on April 18, 2013. The Board also wishes to acknowledge and recognize the very significant contribution of Mr. Riddell and the part that he has played in making Alaris a great success.

Alaris Royalty Corp. Releases 2012 Financial Results
Marketwire - Thu Mar 14, 7:02AM CDT
NOT FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAW.

Alaris Royalty Corp. Declares Monthly Dividend
Marketwire - Tue Feb 19, 7:04AM CST
Alaris Royalty Corp. ("Alaris" or the "Corporation" (TSX: AD) announces that the Board of Directors of the Corporation has declared a dividend of $0.105 per common share. The dividend is payable on March 15, 2013 to holders of record on February 28, 2013. The ex-dividend date is February 26, 2013.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 237

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
Alaska's Insurance Maze: Coverage Over Cheap Policies

Updated Category News Views 171

Beyond Premiums: Assessing Real Coverage Needs The Alaskan wilderness isn't just home to stunning views; it's also a land where insurance needs to go beyond the average cookie-cutter policy. You'd think the cheapest option would suffice, but that's where residents might trip into financial quicksand. Devery Prince, a seasoned insurance principal, sheds light on why...

Continue Reading
CSTS Unveils PremierX in NYC: A Bold Entertainment Move

Updated Category News Views 228

Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...

Continue Reading
DIRECTV Bags New NHL Deals: Stakes for Sports Fans

Updated Category News Views 229

NHL Fans, Strap in: DIRECTV Expands Its Lineup In a world where keeping up with your favorite team gets tougher each day, DIRECTV just lobbed a puck right into the net with their latest play. They've snagged a multi-year deal with the NHL for the Carolina Hurricanes, Columbus Blue Jackets, Minnesota Wild, and St. Louis Blues networks. It's a game changer, folks. If you...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 164

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 145

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Amgen's IMDELLTRA® Shows Promise in SCLC Battle

Updated Category News Views 408

Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...

Continue Reading
Axon Body 5: A Leap Forward in AI for Public Safety

Updated Category News Views 284

Axon Raises the Stakes with Body 5 Camera Boy, oh boy, Axon's dropped a bombshell with the Body 5. We're talking a colossal leap into the AI era for public safety, and if you're in the biz, you can't just shrug this one off. We're looking at 25 times the AI processing power compared to Axon's old units. That's right, I said twenty-five. Real-time situational awareness in...

Continue Reading
Spooky Dining at CARNE: A Halloween Hit in Oxnard

Updated Category News Views 242

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 0

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading

Top 5 Most Recently Viewed Articles

SoftBank Expands AI Infrastructure with DigitalBridge Deal

Updated Category News Views 109

SoftBank's Strategic Move in AI Infrastructure SoftBank Group Corp. has recently announced its plans to acquire DigitalBridge Group Inc. in a cash deal worth approximately $4 billion. This move is seen as a pivotal step in SoftBank's commitment to scaling its infrastructure capabilities for artificial intelligence globally. Details of the Acquisition Under the terms of...

Continue Reading
Nio's Bold Moves in the EV Space: What Investors Should Know

Updated Category News Views 158

Forget the Noise, Nio's Got a Game Plan Back in my day, when you heard whispers about a new product launch, it was either a cause for celebration or a catastrophe waiting to happen. Nio, the fast-rising EV player from China, is set to drop its ES9 SUV this May, and trust me, eyes are on the road. They’ve laid out the details like a clear roadmap. Mark Your Calendars Qin...

Continue Reading
Graycliff Partners Declares Landmark Structures Sale to Cerberus

Updated Category News Views 166

Graycliff Partners Announces the Sale of Landmark Structures Graycliff Partners LP has revealed its decision to sell Landmark Structures, an esteemed provider of water and industrial storage infrastructure solutions, to Cerberus Capital Management, a robust investment firm with a global reach. Landmark Structures specializes in designing, manufacturing, and installing...

Continue Reading
Wedbush Recognizes Uber Technologies as a Top Investment

Updated Category News Views 229

Wedbush Identifies Uber Technologies as a Prime Investment Opportunity In a recent analysis, Wedbush has included Uber Technologies Inc (NYSE: UBER) in its prestigious 'best ideas list.' This recognition stems from the company's attractive risk/reward dynamics, particularly as its shares are trading at a lower multiple. Valuation Insights Currently, Uber's stock is...

Continue Reading
Ververica Enhances Global Impact Through Innovative Partnerships

Updated Category News Views 161

Ververica's Global Influence in Real-Time Data Streaming Ververica, the pioneers behind Apache Flink®, recently highlighted its expanding global impact during the Flink Forward Jakarta event. This flagship occasion, known for focusing on cutting-edge data streaming technologies, served as an excellent platform for Ververica to demonstrate its dedication to helping...

Continue Reading